SULT4A1 is not a sulfotransferase, but a sulfotransferase inhibitor. It forms high affinity heterodimers with other sulfotransferases via a conserved dimerisation site in its carboxyl terminus attenuating catalytic activity. Consequently, it is important for the metabolism of numerous important molecules including estrogens, thyroid hormones, neurotransmitters and many therapeutic agents.
Radiotherapy Treatment For Prostate Cancer - A Change In Practice Based On Direct Evidence For Targeting And Toxicity Effects Using Real Outcomes Data
Funder
National Health and Medical Research Council
Funding Amount
$555,129.00
Summary
Radiotherapy for prostate cancer treatment will be more effective when we have better knowledge of what patient anatomy needs to be targeted, and what needs to be avoided. This project will combine data collected during a large Australasian prostate cancer radiotherapy trial, ‘RADAR’, with data collected using new patient imaging methods to determine how patient anatomy impacts on the effectiveness of their treatment and the side-effects they experience.
Transient Receptor Potential Channels, Calcium And Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$410,284.00
Summary
This research outlined in this application aims to uncover the molecular mechanisms that cause Alzheimer's disease (AD). Specifically the research will examine the mechanism by which Abeta, a protein which plays a central role in AD, causes neurodegeneration. The significance of this work is that it may help to identify new targets for AD drug development.
Polymyxin-like Lipopeptide Antibiotics Of The Future
Funder
National Health and Medical Research Council
Funding Amount
$335,323.00
Summary
Polymyxins are now being clinically used as the ‘last-line’ therapy for infections caused by multidrug-resistant Gram-negative ‘superbugs’. For the first time our novel approach will interface chemistry and biology of the polymyxins with the purpose of creating a new generation of safer and more efficacious polymyxin antibiotics.
While is important to prevent vitamin D deficiency, controversies exist about optimal vitamin D intakes and concentrations. Our aim is to evaluate safety concerns with dosages of vitamin D which are routinely promoted for unsupervised public use with over the counter products. We will do this by evaluating long-term health effects for infant vitamin D supplementation, and by using a genetic approach to evaluate the causal effects of high vitamin D and calcium concentrations.
Altered Nuclear Trafficking And Nuclear Body Dynamics As Drivers Of Ataxin-1 Toxicity
Funder
National Health and Medical Research Council
Funding Amount
$755,190.00
Summary
Ataxias are a large group of neurodegenerative disorders in which balance, motor skills and memory are progressively lost. While mutations in specific proteins do cause certain hereditary ataxias, the mechanisms of their detrimental actions is unclear. Our studies probe the toxic mechanisms of the ataxin-1 protein, focusing on its partners and stress-initiated formation of a toxic hydrogel state. The outcomes will define impacts on cellular protein movement in neurodegeneration more broadly.
Heparin-induced Thrombocytopenia And Thrombosis: Better Understanding Of Pathogenesis And Improving Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$653,137.00
Summary
Heparin, a widely used drug, can cause an adverse effect which results in a fall of the platelet count and the development of serious thrombosis. This drug complication is mediated by an immune mechanism. This proposal aims to provide a better understanding of the disease mechanism. It also aims to develop a new test that will improve the diagnosis, and to produce a novel drug that will effectively suppress the immune reaction and improve the treatment.
A Nanostructured Drug Delivery Approach For Improved Colorectal Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$560,072.00
Summary
Based on nanotechnology a new medicine will be developed for chemotherapy drugs. Drugs that are currently only delivered by injection will be able to be taken as an orally dosed tablet. A novel therapy for colorectal cancer will be advanced with potential improved clinical outcomes and reduced side-effects, e.g. nausea and diarrhoea. Cancer patients will no longer need to visit the hospital for injection therapy and therefore reducing the burden on the health service.
Prevention Of Heart Damage During Anthracycline Cancer Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$327,214.00
Summary
Doxorubicin is an effective medicine widely used for the treatment of cancer. However, it can cause heart damage, which not only creates a new health problem, but also limits the length of doxorubicin treatment cancer patients can receive, and therefore the likelihood of cancer cure. Preventing heart damage by doxorubicin is therefore important to improve overall cancer cure rates and patient health. This study aims to develop new medications to prevent heart damage during cancer chemotherapy.
Regulation Of Drug Detoxifying UDP Glucuronosyltransferases
Funder
National Health and Medical Research Council
Funding Amount
$590,945.00
Summary
Some organs in the body are particularly sensitive to fat-soluble chemicals taken in from the environment or present in food. They are also sensitive to hormones and other small molecule products of metabolism. Controlling the levels of these potentially toxic chemicals is essential in order to maintain the health of the organ. In this work we will investigate the regulation of detoxifying enzymes that protect these organs by inactivating and hastening the elimination of fat-soluble chemicals.